Showing 1181-1190 of 1211 results for "".
- Visioneering Technologies Selects Corneal Lens Corporation NZ and Contact Lens Centre Australia to Distribute NaturalVue Brand Contact Lenses in ANZhttps://modernod.com/news/visioneering-technologies-selects-corneal-lens-corporation-nz-and-contact-lens-centre-australia-to-distribute-naturalvue-brand-contact-lenses-in-anz/2479825/Visioneering Technologies announced that it has signed an agreement with Corneal Lens Corporation (CLC) and its associated company Contact Lens Centre Australia (CLCA), making them authorized distributors of Visioneering’s NaturalVue (etafilcon A) Brand 1 Day Contact Lenses in New Zealand and Aus
- ASCRS Releases Preliminary CyPass Withdrawal Consensus Statementhttps://modernod.com/news/ascrs-releases-preliminary-cypass-withdrawal-consensus-statement/2479843/The American Society of Cataract and Refractive Surgery convened a CyPass Withdrawal Task Force to review the data from the COMPASS-XT study and related research and develop an independent physician guidance document associated with the voluntary withdrawal of Alcon’s CyPass Micro-Stent. To
- Novartis to File for New Lucentis (Ranibizumab) Indication in Retinopathy of Prematurity (ROP)https://modernod.com/news/novartis-to-file-for-new-lucentis-ranibizumab-indication-in-retinopathy-of-prematurity-rop/2479845/Novartis announced results from a phase 3 study of Lucentis (ranibizumab) versus laser surgery (the current standard of care) in premature infants with retinopathy of prematurity (ROP). Unlike laser surgery, which damages eye tissue and can be associated with significant complications such as hig
- Positive PEACHTREE Data to be Highlighted at Euretina 2018https://modernod.com/news/positive-peachtree-data-to-be-highlighted-at-euretina-2018/2479871/Clearside Biomedical announced that data from PEACHTREE, its pivotal phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by Ron Neumann, MD, Uveitis Specialist at Maccabi Health Services, Tel Aviv, Israel and co-Chair of
- NuSight Medical Launches NuLids for the Treatment of Dry Eyehttps://modernod.com/news/nusight-medical-launches-nulids-for-the-treatment-of-dry-eye/2480078/NuSight Medical has introduced The NuLids System, a doctor-prescribed, home-use medical device that efficiently treats dry eye by gently stimulating, de-capping, and rejuvenating the meibomian glands to a healthier state. The system was introduced at the American Optometric Association mee
- Alcon to Showcase New Products, Commitment to ECP Education at 2018 Optometry’s Meetinghttps://modernod.com/news/alcon-to-showcase-new-products-commitment-to-ecp-education-at-2018-optometrys-meeting/2480083/Alcon will introduce new products and educational resources to eye care professional (ECP) and paraoptometric audiences at this year’s American Optometric Association (AOA) Optometry’s Meeting taking place June 20-24 in Denver. Notably, Leatrice Eiseman, executive director at the Pantone C
- Alcon Launches Social Media Campaign to Educate Cataract Patients on Treatment Optionshttps://modernod.com/news/alcon-launches-social-media-campaign-to-educate-cataract-patients-on-treatment-options/2480106/Alcon is launching a digital campaign, “See What You’re Missing,” to empower people to overcome the “FOMO” (fear of missing out) that can be associated with living with cataracts. The new campaign, launched during Cataract Awareness Month, will arm millions of Americans with information to
- Wize Pharma Announces Presentation of New Data on LO2A in the Treatment of Dry Eye Syndrome in Patients with Sjögren’s Syndromehttps://modernod.com/news/wize-pharma-announces-presentation-of-new-data-on-lo2a-in-the-treatment-of-dry-eye-syndrome-in-patients-with-sjogrens-syndrome/2480143/Wize Pharma announced recently reported new data on a formula known as LO2A, a product that Wize has in-licensed certain rights to purchase, market, sell and distribute. The poster presentation presented at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting
- Nicox Presents Scientific Data for NCX 667 at ARVOhttps://modernod.com/news/nicox-presents-scientific-data-for-ncx-667-at-arvo/2480179/Nicox announced a poster presentation highlighting scientific data for NCX 667, a novel nitric oxide (NO) donating compound, at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, one of the key scientific events in the ophthalmology calendar, being held on April
- ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eye Syndromehttps://modernod.com/news/regentree-presents-results-of-a-comparison-study-of-rgn-259-and-approved-prescription-drugs-for-dry-eye-syndrome/2480185/ReGenTree, a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals, announced that the company presented results of a comparison study of RGN-259 and marketed products for dry eye syndrome in a dry eye mouse model at ARVO (The Association for Research in Vision and Ophthalmology)